>アジア太平洋地域の眼痛市場、疾患タイプ別（眼疾患を伴う眼痛と一次眼疾患を伴わない眼痛）、タイプ別（診断と治療）、用途別（結膜炎、角膜剥離、眼瞼炎、麦粒腫、虹彩炎、副鼻腔炎、偏頭痛、緑内障、その他）、投与経路別（局所、眼周囲、眼内、経口、その他）、薬剤タイプ別（処方薬と市販薬）、人口タイプ別（成人と高齢者）、エンドユーザー別（病院、専門クリニック、在宅医療環境、眼科センター、外来手術センター、その他）、流通チャネル別（直接入札、病院薬局、小売薬局、オンライン薬局、その他）、国別（中国、韓国、日本、インド、オーストラリア、シンガポール、マレーシア、インドネシア、タイ、フィリピン、ベトナム、その他のアジア太平洋地域） – 業界動向と2025年までの予測2028年。
市場分析と洞察: アジア太平洋地域の眼痛市場
アジア太平洋地域の眼痛市場は、2021年から2028年の予測期間に成長すると予想されています。データブリッジマーケットリサーチは、市場は2021年から2028年の予測期間に9.0%という最高のCAGRで成長し、2028年までに3億2,276万米ドルに達すると分析しています。不衛生で座りがちなライフスタイルの増加は、アジア太平洋地域の眼痛市場の成長の原動力となっています。
眼痛としても知られる眼痛は、一般的には軽い刺激によって起こりますが、深刻な病気の症状であることは稀です。ほとんどの場合、痛みは薬やそれ以上の治療をしなくても治まり、自己免疫システムによって回復します。しかし、根本的な原発性眼疾患を伴う眼痛は、タイムリーな治療が必要です。眼痛は一般的に 2 つのカテゴリに分類されます。1 つは眼痛で、眼の表面に起こり、引っかくような、灼熱感、または痒みを感じます。これらは、まつ毛、異物、感染、または外傷によって引き起こされます。多くの場合、眼痛は点眼薬と局所ステロイドまたは NSAIDs で治療されます。眼痛は、結膜炎、コンタクトレンズの刺激、角膜擦過傷、外傷、眼瞼炎、および麦粒腫など、根本的な原発性眼疾患によって起こります。刺激療法などの他の高度な治療法も、適切に診断された重度の神経性眼痛に使用されます。
不衛生で座りがちな生活習慣の増加、眼科疾患の罹患率の上昇、眼痛が、アジア太平洋地域の眼痛市場の原動力となっています。眼関連疾患に対する人々の意識の高まりと眼性片頭痛の症例の増加が、市場の成長をさらに後押ししています。眼科治療薬の副作用と眼科治療および投薬の高コストが、アジア太平洋地域の眼痛市場の成長を抑制しています。研究開発活動の増加、医療費および可処分所得の増加、および高齢者人口の増加は、アジア太平洋地域の眼痛市場にとっての機会となっています。眼科治療のための医療施設の不足と厳格な規制枠組みは、アジア太平洋地域の眼痛市場の成長にとって課題となっています。
アジア太平洋の眼痛市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の分析が提供されています。分析と眼痛市場のシナリオを理解するには、アナリスト概要について Data Bridge Market Research にお問い合わせください。当社のチームが、希望する目標を達成するための収益影響ソリューションの作成をお手伝いします。
アジア太平洋地域の眼痛市場の範囲と市場規模
アジア太平洋地域の眼痛市場は、疾患の種類、タイプ、用途、投与経路、薬剤の種類、人口の種類、エンドユーザー、流通チャネルに基づいてセグメント化されています。セグメント間の成長は、ニッチな成長分野と市場にアプローチするための戦略を分析し、コアアプリケーション領域とターゲット市場の違いを決定するのに役立ちます。
- アジア太平洋地域の眼痛市場は、疾患の種類に基づいて、眼疾患を伴う眼痛と、主な眼疾患を伴わない眼痛に分類されます。2021年には、一般の人々の間で眼疾患に関する意識が高まっているため、眼疾患を伴う眼痛のセグメントが眼痛市場を支配すると予想されます。
- タイプ別に見ると、アジア太平洋地域の眼痛市場は診断と治療に分かれています。2021年には、アジア諸国や研究機関での研究活動が活発化しているため、診断セグメントが市場を独占すると予想されます。
- 用途に基づいて、アジア太平洋地域の眼痛市場は、結膜炎、角膜擦過傷、眼瞼炎、ものもらい、虹彩炎、副鼻腔炎、片頭痛、緑内障、その他に分類されます。2021年には、この地域の発展途上国でこの疾患の有病率が高いため、緑内障セグメントが市場を支配すると予想されます。
- 投与経路に基づいて、アジア太平洋地域の眼痛市場は、局所、眼周囲、眼内、経口、その他に分類されます。2021 年には、患者のコンプライアンスが高いため、局所セグメントが市場を支配すると予想されます。
- アジア太平洋地域の眼痛薬市場は、薬剤の種類に基づいて、処方薬と市販薬に分類されます。2021年には、この地域での厳格な規制管理により、処方薬セグメントが市場を支配すると予想されます。
- アジア太平洋地域の眼痛市場は、人口タイプに基づいて、成人と高齢者に分類されます。2021年には、ガジェットの多さと目のケア保護の少なさにより、成人セグメントが市場を支配すると予想されます。
- エンドユーザーに基づいて、アジア太平洋地域の眼痛市場は、病院、専門クリニック、在宅医療、眼科センター、外来手術センター、その他に分類されます。2021年には、医療費の高騰と病院建設により、病院セグメントが市場を支配すると予想されます。
- 流通チャネルに基づいて、アジア太平洋地域の眼痛市場は、直接入札、病院薬局、小売薬局、オンライン薬局、その他に分類されます。2021年には、直接入札セグメントが、ユーザーの利益を伴う顧客のニーズに応じた製品を具体的に提供するため、市場を支配すると予想されます。
アジア太平洋地域の眼痛市場の国別分析
アジア太平洋地域の眼痛市場が分析され、上記の国、疾患の種類、タイプ、用途、投与経路、薬剤の種類、人口の種類、エンドユーザー、流通チャネル別に市場規模の情報が提供されます。
アジア太平洋地域の眼痛市場レポートで取り上げられている国は、中国、韓国、日本、インド、オーストラリア、シンガポール、マレーシア、インドネシア、タイ、フィリピン、およびその他のアジア太平洋地域です。
アジア太平洋地域の日本における処方薬セグメントは、眼科疾患の増加により、2021年から2028年の予測期間に最も高い成長率で成長すると予想されています。中国における処方薬セグメントは、人々の座りがちなライフスタイルの増加により、2番目に支配的な市場となっています。インドは、アジア太平洋地域で3番目に大きい市場です。この国では、眼科病院の数が最も多いため、処方薬セグメントが支配的になると予想されています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。また、アジア太平洋ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面する課題、販売チャネルの影響を考慮しながら、国別データの予測分析を提供します。
眼痛治療に対する認知度を高めるための主要市場プレーヤーによる戦略的活動の拡大が、アジア太平洋地域の 眼痛市場の成長を後押ししています。
アジア太平洋の眼痛市場では、特定の市場における各国の成長に関する詳細な市場分析も提供されます。さらに、市場プレーヤーの戦略と地理的なプレゼンスに関する詳細な情報も提供されます。データは、2010 年から 2019 年までの履歴期間で利用できます。
競争環境とアジア太平洋地域の 眼痛治療薬市場シェア分析
アジア太平洋の眼痛市場の競争状況では、競合他社の詳細が提供されます。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と広さ、アプリケーションの優位性、技術ライフライン曲線などがあります。提供されている上記のデータ ポイントは、アジア太平洋の眼痛市場への会社の重点にのみ関連しています。
アジア太平洋地域の眼痛治療薬市場で取引を行っている主要企業には、ジョンソン・エンド・ジョンソン・サービス社、ファイザー社、メルク・シャープ・アンド・ドーム社（メルク社の子会社）、エアリー・ファーマシューティカルズ社、サン・ファーマシューティカル・インダストリーズ社、ボシュ・アンド・ロム社、ノバルティス社、アラガン社（アッヴィ社の子会社）、フォルモサファーマ・ファーマシューティカル社、その他国内企業があります。DBMR のアナリストは、競争上の強みを理解し、各競合他社の競合分析を個別に提供しています。
世界中の企業によって多くの契約や協定も開始され、アジア太平洋地域の眼痛市場の成長を加速させています。
例えば、
- 2021年9月、メルク・アンド・カンパニーの子会社であるメルク・シャープ・アンド・ドーム社は、モルガン・スタンレーの第19回年次会議でバーチャル炉辺談話に参加したことを発表しました。これにより、同社はより多くのアジア太平洋地域の顧客を引き付けることができました。
- 2019年5月、ファイザー社はマサチューセッツ州アンドーバーに新しい製造施設を開設し、事業を拡大しました。同社はこの取り組みにより、患者の治療選択肢を向上させる医薬品の製造を強化しました。この取り組みにより、同社は研究開発製造チームとの強力なパートナーシップを築くことができました。
市場プレーヤーによるコラボレーション、製品の発売、事業拡大、賞や表彰、合弁事業、その他の戦略は、眼痛市場における同社の足跡を強化し、組織の利益成長にも貢献します。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC OCULAR PAIN MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 ASIA PACIFIC OCULAR PAIN MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DISEASE TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
4.3 AVERAGE PRICING ANALYSIS OF VARIOUS TREATMENT OPTIONS
4.4 VOLUME OF PRESCRIPTION
5 PIPELINE ANALYSIS
6 REGIONAL SUMMARY
6.1 NORTH AMERICA
6.2 EUROPE
6.3 ASIA-PACIFIC
6.4 SOUTH AMERICA
6.5 THE MIDDLE EAST AND AFRICA
7 ASIA PACIFIC OCULAR PAIN MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE
8.1.2 RISING PREVALENCE OF OPHTHALMIC DISORDERS AND OCULAR PAINS
8.1.3 INCREASING AWARENESS AMONG PEOPLE FOR EYE-RELATED DISEASES
8.1.4 GROWING CASES OF OCULAR MIGRAINE
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS OF EYE TREATMENT MEDICINES
8.2.2 HIGH COST OF EYE TREATMENT AND MEDICATION
8.3 OPPORTUNITIES
8.3.1 RISING HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
8.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
8.3.3 INCREASING GERIATRIC POPULATION
8.4 CHALLENGES
8.4.1 STRINGENT RULES & REGULATIONS
8.4.2 LACK OF HEALTHCARE FACILITIES FOR EYE TREATMENT
9 IMPACT OF COVID-19 PANDEMIC ON THE ASIA PACIFIC OCULAR PAIN MARKET
9.1 PRICE IMPACT
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 ASIA PACIFIC OCULAR PAIN MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 OCULAR PAIN WITH EYE DISEASES
10.2.1 OCULAR PAIN WITH RED EYE
10.2.2 OCULAR PAIN WITHOUT RED EYE
10.3 OCULAR PAIN WITHOUT PRIMARY EYE DISEASES
10.3.1 OCULAR MIGRAINE
10.3.2 GIANT CELL ARTERITIS
10.3.3 TRIGEMINAL NEURALGIAS
10.3.4 CAVERNOUS SINUS AND SUPERIOR FISSURE PROCESSES
10.3.5 CAROTID ARTERY DISSECTION
10.3.6 CAROTIDYNIA
10.3.7 OTHERS
11 ASIA PACIFIC OCULAR PAIN MARKET, BY TYPE
11.1 OVERVIEW
11.2 DIAGNOSIS
11.2.1 SENSORY TESTING
11.2.1.1 HAND LIGHT EXAMINATION
11.2.1.2 DIRECT OPHTHALMOSCOPIC EXAMINATIONS
11.2.1.3 SLIT LAMP EXAMINATION
11.2.1.4 FLUORESCEIN EXAMINATION
11.2.2 IMAGING TEST
11.2.2.1 CONFOCAL MICROSCOPY
11.2.2.2 FUNCTIONAL MRI
11.3 TREATMENT
11.3.1 LOCAL TREATMENT
11.3.1.1 TOPICAL STEROID
11.3.1.1.1 LOTEPREDNOL
11.3.1.1.2 DEXAMETHASONE
11.3.1.1.3 PREDNISOLONE
11.3.1.1.4 FLUOROMETHOLONE
11.3.1.1.5 OTHERS
11.3.1.2 NONSTEROIDAL ANTI-INFLAMMATORY (NSAID)
11.3.1.2.1 BROMFENAC
11.3.1.2.2 KETOROLAC
11.3.1.2.3 NEPAFENAC
11.3.1.2.4 DICLOFENAC
11.3.1.2.5 OTHERS
11.3.1.3 OTHERS
11.3.2 STIMULATION THERAPIES
11.3.2.1 DEEP BRAIN STIMULATION
11.3.2.2 TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS)
11.3.2.3 REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (RTMS)
11.3.2.4 SCRAMBLER THERAPY
11.3.2.5 OTHERS
11.3.3 OTHERS
12 ASIA PACIFIC OCULAR PAIN MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 GLAUCOMA
12.3 BLEPHARITIS
12.4 CONJUNCTIVITIS
12.5 CORNEAL ABRASION
12.6 STY
12.7 IRITIS
12.8 SINUSITIS
12.9 MIGRAINES
12.1 OTHERS
13 ASIA PACIFIC OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 TOPICAL
13.2.1 SOLUTION
13.2.2 GELS
13.2.3 OINTMENTS
13.2.4 OTHERS
13.3 INTRAOCULAR
13.3.1 INTRAVITREAL
13.3.2 INTRACAMERAL
13.4 PERIOCULAR
13.4.1 SUBCONJUNCTIVAL
13.4.2 SUBTENON
13.4.3 PERIBULBAR
13.4.4 RETROBULBAR
13.5 ORAL
13.5.1 TABLETS
13.5.2 CAPSULE
13.5.3 OTHERS
13.6 OTHERS
14 ASIA PACIFIC OCULAR PAIN MARKET, BY DRUG TYPE
14.1 OVERVIEW
14.2 PRESCRIPTION
14.3 OVER THE COUNTER
15 ASIA PACIFIC OCULAR PAIN MARKET, BY POPULATION TYPE
15.1 OVERVIEW
15.2 ADULTS
15.3 GERIATRIC
16 ASIA PACIFIC OCULAR PAIN MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALTY CLINICS
16.4 HOME HEALTHCARE
16.5 OPHTHALMOLOGY CENTERS
16.6 AMBULATORY SURGICAL CENTERS
16.7 OTHERS
17 ASIA PACIFIC OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 HOSPITAL PHARMACY
17.4 RETAIL PHARMACY
17.5 ONLINE PHARMACY
17.6 OTHERS
18 ASIA PACIFIC OCULAR PAIN MARKET, BY GEOGRAPHY
18.1 ASIA-PACIFIC
18.1.1 JAPAN
18.1.2 CHINA
18.1.3 INDIA
18.1.4 SOUTH KOREA
18.1.5 AUSTRALIA
18.1.6 SINGAPORE
18.1.7 THAILAND
18.1.8 MALAYSIA
18.1.9 INDONESIA
18.1.10 PHILIPPINES
18.1.11 VIETNAM
18.1.12 REST OF ASIA-PACIFIC
19 ASIA PACIFIC OCULAR PAIN MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
20 SWOT ANALYSIS
21 COMPANY PROFILE
21.1 BAUSCH & LOMB INCORPORATED
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 NOVARTIS AG
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENT
21.4 OMEROS CORPORATION
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 PRODUCT PORTFOLIO
21.4.4 RECENT DEVELOPMENTS
21.5 AKORN OPERATING COMPANY LLC
21.5.1 COMPANY SNAPSHOT
21.5.2 COMPANY SHARE ANALYSIS
21.5.3 PRODUCT PORTFOLIO
21.5.4 RECENT DEVELOPMENTS
21.6 AERIE PHARMACEUTICALS, INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ALDEYRA THERAPEUTICS, INC.
21.7.1 COMPANY SNAPSHOT
21.7.2 PRODUCT PORTFOLIO
21.7.3 RECENT DEVELOPMENTS
21.8 ALLAKOS INC.
21.8.1 COMPANY SNAPSHOT
21.8.2 PRODUCT PORTFOLIO
21.8.3 RECENT DEVELOPMENT
21.9 ALLERGAN (AN ABBVIE COMPANY)
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENTS
21.1 EYEPOINT PHARMACEUTICALS, INC.
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENTS
21.11 FERA PHARMACEUTICALS
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENTS
21.12 FORMOSAPHARMA PHARMACEUTICAL INC.
21.12.1 COMPANY SNAPSHOT
21.12.2 PRODUCT PORTFOLIO
21.12.3 RECENT DEVELOPMENT
21.13 IACTA PHARMACEUTICALS, INC.
21.13.1 COMPANY SNAPSHOT
21.13.2 PRODUCT PORTFOLIO
21.13.3 RECENT DEVELOPMENTS
21.14 JOHNSON & JOHNSON SERVICES, INC.
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 KALA PHARMACEUTICALS
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENTS
21.17 NOVALIQ GMBH
21.17.1 COMPANY SNAPSHOT
21.17.2 PRODUCT PORTFOLIO
21.17.3 RECENT DEVELOPMENTS
21.18 OCULAR THERAPEUTIX, INC.
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENTS
21.19 OKYO PHARMA LIMITED
21.19.1 COMPANY SNAPSHOT
21.19.2 PRODUCT PORTFOLIO
21.19.3 RECENT DEVELOPMENTS
21.2 PFIZER, INC.
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 PHARMALEADS SA
21.21.1 COMPANY SNAPSHOT
21.21.2 PRODUCT PORTFOLIO
21.21.3 RECENT DEVELOPMENT
21.22 SITEONE THERAPEUTICS, INC.
21.22.1 COMPANY SNAPSHOT
21.22.2 PRODUCT PORTFOLIO
21.22.3 RECENT DEVELOPMENT
21.23 SYLENTIS
21.23.1 COMPANY SNAPSHOT
21.23.2 PRODUCT PORTFOLIO
21.23.3 RECENT DEVELOPMENT
21.24 TALLC INC.
21.24.1 COMPANY SNAPSHOT
21.24.2 PRODUCT PORTFOLIO
21.24.3 RECENT DEVELOPMENT
21.25 TARSIER PHARMA LTD.
21.25.1 COMPANY SNAPSHOT
21.25.2 PRODUCT PORTFOLIO
21.25.3 RECENT DEVELOPMENT
21.26 VYLUMA
21.26.1 COMPANY SNAPSHOT
21.26.2 PRODUCT PORTFOLIO
21.26.3 RECENT DEVELOPMENT
22 QUESTIONNAIRE
23 RELATED REPORTS
表のリスト
TABLE 1 AVERAGE PRICING ANALYSIS OF VARIOUS TREATMENT PRODUCTS
TABLE 2 VOLUME OF PRESCRIPTION (%)
TABLE 3 ASIA PACIFIC OCULAR PAIN MARKET, PIPELINE ANALYSIS
TABLE 4 ASIA PACIFIC OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 5 ASIA PACIFIC OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 ASIA PACIFIC OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 7 ASIA PACIFIC OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA PACIFIC OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 9 ASIA PACIFIC OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 ASIA PACIFIC DIAGNOSIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA PACIFIC DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 ASIA PACIFIC SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 13 ASIA PACIFIC IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 ASIA PACIFIC TREATMENT IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 ASIA PACIFIC TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 ASIA PACIFIC LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 ASIA PACIFIC TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 ASIA PACIFIC NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 ASIA PACIFIC STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 ASIA PACIFIC OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 21 ASIA PACIFIC GLAUCOMA IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 ASIA PACIFIC BLEPHARITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 ASIA PACIFIC CONJUNCTIVITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 ASIA PACIFIC CORNEAL ABRASION IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 ASIA PACIFIC STY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 ASIA PACIFIC IRITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 ASIA PACIFIC SINUSITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 ASIA PACIFIC MIGRAINES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 ASIA PACIFIC OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 ASIA PACIFIC OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 ASIA PACIFIC TOPICAL IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 ASIA PACIFIC TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 33 ASIA PACIFIC INTRAOCULAR IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 ASIA PACIFIC INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 35 ASIA PACIFIC PERIOCULAR IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 ASIA PACIFIC PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 37 ASIA PACIFIC ORAL IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 ASIA PACIFIC ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 39 ASIA PACIFIC OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 ASIA PACIFIC OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 41 ASIA PACIFIC PRESCRIPTION IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 ASIA PACIFIC OVER THE COUNTER IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 ASIA PACIFIC OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 44 ASIA PACIFIC ADULTS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 ASIA PACIFIC GERIATRIC IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 ASIA PACIFIC OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 47 ASIA PACIFIC HOSPITALS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 ASIA PACIFIC SPECIALTY CLINICS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 ASIA PACIFIC HOME HEALTHCARE IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 50 ASIA PACIFIC OPHTHALMOLOGY CENTERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 51 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 ASIA PACIFIC OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 53 ASIA PACIFIC OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 54 ASIA PACIFIC DIRECT TENDER IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 55 ASIA PACIFIC HOSPITAL PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 56 ASIA PACIFIC RETAIL PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 57 ASIA PACIFIC ONLINE PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 58 ASIA PACIFIC OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 59 ASIA-PACIFIC OCULAR PAIN MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 60 ASIA-PACIFIC OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 61 ASIA-PACIFIC OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 62 ASIA-PACIFIC OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 63 ASIA-PACIFIC OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 ASIA-PACIFIC DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 ASIA-PACIFIC SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 ASIA-PACIFIC IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 ASIA-PACIFIC TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 ASIA-PACIFIC LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 ASIA-PACIFIC TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 70 ASIA-PACIFIC NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 71 ASIA-PACIFIC STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 72 ASIA-PACIFIC OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 73 ASIA-PACIFIC OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 74 ASIA-PACIFIC TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 75 ASIA-PACIFIC INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 76 ASIA-PACIFIC PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 77 ASIA-PACIFIC ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 78 ASIA-PACIFIC OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 79 ASIA-PACIFIC OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 80 ASIA-PACIFIC OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 81 ASIA-PACIFIC OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 82 JAPAN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 83 JAPAN OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 84 JAPAN OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 85 JAPAN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 86 JAPAN DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 JAPAN SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 88 JAPAN IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 JAPAN TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 JAPAN LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 JAPAN TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 JAPAN NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 JAPAN STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 94 JAPAN OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 95 JAPAN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 JAPAN TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 JAPAN INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 98 JAPAN PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 99 JAPAN ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 100 JAPAN OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 101 JAPAN OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 102 JAPAN OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 103 JAPAN OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 104 CHINA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 105 CHINA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 106 CHINA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 107 CHINA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 CHINA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 CHINA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 CHINA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 CHINA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 CHINA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 113 CHINA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 114 CHINA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 115 CHINA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 116 CHINA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 117 CHINA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 118 CHINA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 119 CHINA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 120 CHINA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 121 CHINA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 122 CHINA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 123 CHINA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 124 CHINA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 125 CHINA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 126 INDIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 127 INDIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 128 INDIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 129 INDIA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 INDIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 INDIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 INDIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 133 INDIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 134 INDIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 135 INDIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 136 INDIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 137 INDIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 INDIA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 139 INDIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 140 INDIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 141 INDIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 142 INDIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 143 INDIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 144 INDIA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 145 INDIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 146 INDIA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 147 INDIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 148 SOUTH KOREA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 149 SOUTH KOREA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 150 SOUTH KOREA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 151 SOUTH KOREA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 152 SOUTH KOREA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 153 SOUTH KOREA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 154 SOUTH KOREA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 155 SOUTH KOREA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 SOUTH KOREA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 SOUTH KOREA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 SOUTH KOREA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 159 SOUTH KOREA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 160 SOUTH KOREA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 161 SOUTH KOREA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 162 SOUTH KOREA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 163 SOUTH KOREA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 164 SOUTH KOREA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 165 SOUTH KOREA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 166 SOUTH KOREA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 167 SOUTH KOREA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 168 SOUTH KOREA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 169 SOUTH KOREA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 170 AUSTRALIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 171 AUSTRALIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 172 AUSTRALIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 173 AUSTRALIA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 AUSTRALIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 AUSTRALIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 AUSTRALIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 AUSTRALIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 178 AUSTRALIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 179 AUSTRALIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 180 AUSTRALIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 181 AUSTRALIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 182 AUSTRALIA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 183 AUSTRALIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 184 AUSTRALIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 185 AUSTRALIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 186 AUSTRALIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 187 AUSTRALIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 188 AUSTRALIA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 189 AUSTRALIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 190 AUSTRALIA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 191 AUSTRALIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 192 SINGAPORE OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 193 SINGAPORE OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 194 SINGAPORE OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 195 SINGAPORE OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 196 SINGAPORE DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 197 SINGAPORE SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 198 SINGAPORE IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 199 SINGAPORE TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 200 SINGAPORE LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 201 SINGAPORE TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 202 SINGAPORE NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 203 SINGAPORE STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 204 SINGAPORE OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 205 SINGAPORE OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 206 SINGAPORE TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 207 SINGAPORE INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 208 SINGAPORE PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 209 SINGAPORE ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 210 SINGAPORE OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 211 SINGAPORE OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 212 SINGAPORE OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 213 SINGAPORE OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 214 THAILAND OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 215 THAILAND OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 216 THAILAND OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 217 THAILAND OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 218 THAILAND DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 219 THAILAND SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 220 THAILAND IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 221 THAILAND TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 222 THAILAND LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 223 THAILAND TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 224 THAILAND NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 225 THAILAND STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 226 THAILAND OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 227 THAILAND OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 228 THAILAND TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 229 THAILAND INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 230 THAILAND PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 231 THAILAND ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 232 THAILAND OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 233 THAILAND OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 234 THAILAND OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 235 THAILAND OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 236 MALAYSIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 237 MALAYSIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 238 MALAYSIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 239 MALAYSIA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 240 MALAYSIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 241 MALAYSIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 242 MALAYSIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 243 MALAYSIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 244 MALAYSIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 245 MALAYSIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 246 MALAYSIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 247 MALAYSIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 248 MALAYSIA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 249 MALAYSIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 250 MALAYSIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 251 MALAYSIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 252 MALAYSIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 253 MALAYSIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 254 MALAYSIA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 255 MALAYSIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 256 MALAYSIA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 257 MALAYSIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 258 INDONESIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 259 INDONESIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 260 INDONESIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 261 INDONESIA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 262 INDONESIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 263 INDONESIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 264 INDONESIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 265 INDONESIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 266 INDONESIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 267 INDONESIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 268 INDONESIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 269 INDONESIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 270 INDONESIA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 271 INDONESIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 272 INDONESIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 273 INDONESIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 274 INDONESIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 275 INDONESIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 276 INDONESIA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 277 INDONESIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 278 INDONESIA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 279 INDONESIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 280 PHILIPPINES OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 281 PHILIPPINES OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 282 PHILIPPINES OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 283 PHILIPPINES OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 284 PHILIPPINES DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 285 PHILIPPINES SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 286 PHILIPPINES IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 287 PHILIPPINES TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 288 PHILIPPINES LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 289 PHILIPPINES TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 290 PHILIPPINES NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 291 PHILIPPINES STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 292 PHILIPPINES OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 293 PHILIPPINES OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 294 PHILIPPINES TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 295 PHILIPPINES INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 296 PHILIPPINES PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 297 PHILIPPINES ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 298 PHILIPPINES OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 299 PHILIPPINES OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 300 PHILIPPINES OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 301 PHILIPPINES OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 302 VIETNAM OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 303 VIETNAM OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 304 VIETNAM OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 305 VIETNAM OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 306 VIETNAM DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 307 VIETNAM SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 308 VIETNAM IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 309 VIETNAM TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 310 VIETNAM LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 311 VIETNAM TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 312 VIETNAM NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 313 VIETNAM STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 314 VIETNAM OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 315 VIETNAM OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 316 VIETNAM TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 317 VIETNAM INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 318 VIETNAM PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 319 VIETNAM ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 320 VIETNAM OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 321 VIETNAM OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 322 VIETNAM OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 323 VIETNAM OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 324 REST OF ASIA-PACIFIC OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
図表一覧
FIGURE 1 ASIA PACIFIC OCULAR PAIN MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC OCULAR PAIN MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC OCULAR PAIN MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC OCULAR PAIN MARKET: ASIA PACIFIC VS REGIONAL ANALYSIS
FIGURE 5 ASIA PACIFIC OCULAR PAIN MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC OCULAR PAIN MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC OCULAR PAIN MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC OCULAR PAIN MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 ASIA PACIFIC OCULAR PAIN MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 ASIA PACIFIC OCULAR PAIN MARKET: SEGMENTATION
FIGURE 11 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE IS EXPECTED TO DRIVE THE ASIA PACIFIC OCULAR PAIN MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 OCULAR PAIN WITH EYE DISEASE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC OCULAR PAIN MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC OCULAR PAIN MARKET, AND ASIA-PACIFIC IS PROJECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC OCULAR PAIN MARKET
FIGURE 15 AGEING POPULATION IN THE WORLD (IN MILLIONS)
FIGURE 16 NORTH AMERICA AGEING POPULATION (IN MILLION)
FIGURE 17 EUROPE AGEING POPULATION (IN MILLION)
FIGURE 18 ASIA-PACIFIC AGEING POPULATION (IN MILLION)
FIGURE 19 ASIA PACIFIC OCULAR PAIN MARKET: BY DISEASE TYPE, 2020
FIGURE 20 ASIA PACIFIC OCULAR PAIN MARKET: BY DISEASE TYPE, 2019-2028 (USD MILLION)
FIGURE 21 ASIA PACIFIC OCULAR PAIN MARKET: BY DISEASE TYPE, CAGR (2021-2028)
FIGURE 22 ASIA PACIFIC OCULAR PAIN MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 23 ASIA PACIFIC OCULAR PAIN MARKET: BY TYPE, 2020
FIGURE 24 ASIA PACIFIC OCULAR PAIN MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 25 ASIA PACIFIC OCULAR PAIN MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 26 ASIA PACIFIC OCULAR PAIN MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC OCULAR PAIN MARKET: BY APPLICATION, 2020
FIGURE 28 ASIA PACIFIC OCULAR PAIN MARKET: BY APPLICATION, 2019-2028 (USD MILLION)
FIGURE 29 ASIA PACIFIC OCULAR PAIN MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 30 ASIA PACIFIC OCULAR PAIN MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 ASIA PACIFIC OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 33 ASIA PACIFIC OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 ASIA PACIFIC OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 ASIA PACIFIC OCULAR PAIN MARKET: BY DRUG TYPE, 2020
FIGURE 36 ASIA PACIFIC OCULAR PAIN MARKET: BY DRUG TYPE, 2019-2028 (USD MILLION)
FIGURE 37 ASIA PACIFIC OCULAR PAIN MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 38 ASIA PACIFIC OCULAR PAIN MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 39 ASIA PACIFIC OCULAR PAIN MARKET: BY POPULATION TYPE, 2020
FIGURE 40 ASIA PACIFIC OCULAR PAIN MARKET: BY POPULATION TYPE, 2019-2028 (USD MILLION)
FIGURE 41 ASIA PACIFIC OCULAR PAIN MARKET: BY POPULATION TYPE, CAGR (2021-2028)
FIGURE 42 ASIA PACIFIC OCULAR PAIN MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 43 ASIA PACIFIC OCULAR PAIN MARKET: BY END USER, 2020
FIGURE 44 ASIA PACIFIC OCULAR PAIN MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 45 ASIA PACIFIC OCULAR PAIN MARKET: BY END USER, CAGR (2021-2028)
FIGURE 46 ASIA PACIFIC OCULAR PAIN MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 ASIA PACIFIC OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 48 ASIA PACIFIC OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 49 ASIA PACIFIC OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 50 ASIA PACIFIC OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 ASIA-PACIFIC OCULAR PAIN MARKET: SNAPSHOT (2020)
FIGURE 52 ASIA-PACIFIC OCULAR PAIN MARKET: BY COUNTRY (2020)
FIGURE 53 ASIA-PACIFIC OCULAR PAIN MARKET: BY COUNTRY (2021 & 2028)
FIGURE 54 ASIA-PACIFIC OCULAR PAIN MARKET: BY COUNTRY (2020 & 2028)
FIGURE 55 ASIA-PACIFIC OCULAR PAIN MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 56 ASIA PACIFIC OCULAR PAIN MARKET: COMPANY SHARE 2020 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
